T cell Targeting for Cancers and Autoimmune Diseases
Reference Sustained Effect Theory
Angimmune LLC is the developer of a high potency fusion protein anticancer immunotoxin,
A-dmDT390-bisFv(UCHT1) (Resimmune®). Resimmune® has been granted Orphan Drug Designation for the treatment of Cutaneous T-Cell Lymphoma (CTCL).
This unique bivalent anti-T cell immunotoxin therapy works in two ways:
- Kills malignant T cells, targeting the CD3 receptor.
- Yields repopulated T cells (repopulated in 2 weeks) that may be less hospitable to malignancies.
The therapy has potential application for
With the drug administered in four days versus multiple courses of other treatments, the drug has the potential to reduce both treatment time and expense.
Resimmune® has now progressed to a Phase II Clinical Trial for Cutaneous
The FDA has approved Resimmune® for a clinical trial to evaluate the hypothesis that Resimmune® can act as an immunomodulator of late stage metastatic melanoma when combined with palliative radiation to induce the priming of activated T cells with tumor antigens. Please see our Melanoma Clinical Trials section for more information about this trial at the James Graham Brown Cancer Center in Louisville.
Licensing & Collaboration
Angimmune welcomes inquiries regarding licensing of its technologies.